BR112022011037A2 - Anticorpos ddr1 novos e usos dos mesmos - Google Patents
Anticorpos ddr1 novos e usos dos mesmosInfo
- Publication number
- BR112022011037A2 BR112022011037A2 BR112022011037A BR112022011037A BR112022011037A2 BR 112022011037 A2 BR112022011037 A2 BR 112022011037A2 BR 112022011037 A BR112022011037 A BR 112022011037A BR 112022011037 A BR112022011037 A BR 112022011037A BR 112022011037 A2 BR112022011037 A2 BR 112022011037A2
- Authority
- BR
- Brazil
- Prior art keywords
- ddr1
- antibodies
- new
- present disclosure
- ddr1 antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949300P | 2019-12-17 | 2019-12-17 | |
| PCT/US2020/065618 WO2021127185A1 (en) | 2019-12-17 | 2020-12-17 | Novel ddr1 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011037A2 true BR112022011037A2 (pt) | 2022-09-13 |
Family
ID=76478553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011037A BR112022011037A2 (pt) | 2019-12-17 | 2020-12-17 | Anticorpos ddr1 novos e usos dos mesmos |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230130372A1 (https=) |
| EP (1) | EP4076526A4 (https=) |
| JP (2) | JP2023508277A (https=) |
| CN (1) | CN115443150A (https=) |
| AU (1) | AU2020407089B2 (https=) |
| BR (1) | BR112022011037A2 (https=) |
| CA (1) | CA3160181A1 (https=) |
| IL (1) | IL294019A (https=) |
| MX (1) | MX2022007353A (https=) |
| WO (1) | WO2021127185A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115443150A (zh) * | 2019-12-17 | 2022-12-06 | 德克萨斯大学系统董事会 | 新型ddr1抗体和其用途 |
| CN116023497B (zh) * | 2022-11-09 | 2024-06-21 | 四川大学华西医院 | 抗ddr1抗体及其用途 |
| AU2023379587A1 (en) * | 2022-11-16 | 2025-06-05 | Incendia Therapeutics, Inc. | Methods of treating cancer using anti-ddr1 antibodies and immune checkpoint inhibitors |
| CN120418294A (zh) * | 2022-11-16 | 2025-08-01 | 英森迪亚治疗公司 | 使用抗ddr1抗体治疗癌症的方法 |
| CN118909125B (zh) * | 2024-10-10 | 2025-01-03 | 杭州美赛生物医药科技有限公司 | 抗ddr1抗体及其应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6051397A (en) | 1993-11-16 | 2000-04-18 | Max Planck Gesellschaft Zur Forderung Der Wissenschaften | DNA encoding MCK-10, a novel receptor tyrosine kinase |
| US20020115173A1 (en) | 2000-12-11 | 2002-08-22 | Children's Medical Center Corporation | Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity |
| US7855076B2 (en) | 2002-03-12 | 2010-12-21 | The United States Of America As Represented By The Department Of Health And Human Services | Use of discoidin domain receptor 1 (DDR1) and agents that affect the DDR1/collagen pathway |
| WO2003085125A1 (en) | 2002-04-03 | 2003-10-16 | Agy Therapeutics, Inc. | Use of biomolecular targets in the treatment and visualization of brain tumors |
| US20070025997A1 (en) | 2002-04-03 | 2007-02-01 | Usha Nagavarapu | Use of biomolecular targets in the treatment and visualization of brain tumors |
| US20100166731A1 (en) | 2005-09-30 | 2010-07-01 | Bartz Steven R | Methods and Compositions for Treating Cancer |
| EP1992347A1 (en) | 2007-05-18 | 2008-11-19 | Cellzome Ag | Treatment of DDR1 positive cancer using imatinib |
| US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
| CA2780221A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| AU2011295968B2 (en) | 2010-09-01 | 2017-01-05 | Biogen Ma Inc. | Rapid generation of anti-idiotypic antibodies |
| WO2012085064A1 (en) | 2010-12-23 | 2012-06-28 | Roche Diagnostics Gmbh | Detection of a posttranslationally modified polypeptide by a bi-valent binding agent |
| MX2013011363A (es) * | 2011-04-01 | 2014-04-25 | Sloan Kettering Inst Cancer | Anticuerpos para peptidos citosolicos. |
| US9550835B2 (en) * | 2011-08-23 | 2017-01-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-DDR1 antibody having anti-tumor activity |
| GB201115529D0 (en) * | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
| US10633451B2 (en) | 2012-02-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine |
| HK1204926A1 (en) | 2012-02-29 | 2015-12-11 | 吉联亚生物科技有限公司 | Antibodies to matrix metalloproteinase 9 |
| US11873281B2 (en) | 2012-07-12 | 2024-01-16 | Hangzhou Dac Biotech Co., Ltd. | Conjugates of cell binding molecules with cytotoxic agents |
| US20140086913A1 (en) | 2012-09-24 | 2014-03-27 | Gilead Sciences, Inc. | Anti-ddr1 antibodies |
| WO2014047624A1 (en) * | 2012-09-24 | 2014-03-27 | Gilead Sciences, Inc. | Anti-ddr1 antibodies |
| WO2014140330A1 (en) | 2013-03-15 | 2014-09-18 | Oryzon Genomics, S.A. | Anti-ddr1 internalizing antibodies and their medical use |
| KR102113310B1 (ko) | 2013-09-03 | 2020-05-20 | 아주대학교 산학협력단 | 암 세포 분리용 조성물, 키트 및 이를 이용한 분리 방법 |
| CN115160441A (zh) | 2013-09-26 | 2022-10-11 | 埃博灵克斯股份有限公司 | 双特异性纳米抗体 |
| WO2015081127A2 (en) | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| US20170158762A1 (en) * | 2014-01-30 | 2017-06-08 | Anaptysbio, Inc. | Antibodies directed against discoidin domain receptor family, member 1 (ddr1) |
| IL252192B2 (en) | 2014-11-10 | 2024-03-01 | Del Mar Pharmaceuticals | Dianhydrogalactitol together with radiation to treat non-small-cell carcinoma of the lung and glioblastoma multiforme |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| AU2017228371A1 (en) | 2016-03-04 | 2018-09-13 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| KR20180007924A (ko) | 2016-07-14 | 2018-01-24 | 주식회사 코리아하이텍 | 차량용 빔프로젝터 방열 장치 |
| US20190310250A1 (en) * | 2016-12-16 | 2019-10-10 | Merck Patent Gmbh | Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis |
| CA3047593A1 (en) * | 2017-01-02 | 2018-07-05 | The Board Of Regents Of The University Of Texas System | Anti-lair1 antibodies and their uses |
| CA3055256A1 (en) * | 2017-03-09 | 2018-09-13 | Mab Discovery Gmbh | Antibodies specifically binding to human il-1r7 |
| WO2018183921A1 (en) | 2017-04-01 | 2018-10-04 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
| KR20210122319A (ko) | 2017-04-06 | 2021-10-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 비스-링키지를 사용한 세포독성 약물의 접합 |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| WO2018237287A1 (en) * | 2017-06-22 | 2018-12-27 | Apexigen, Inc. | Anti-vista antibodies and methods of use |
| EP3655961A4 (en) | 2017-07-17 | 2021-09-01 | Massachusetts Institute of Technology | HEALTHY AND SICK BARRIER TISSUE CELL ATLAS |
| MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
| EP3621652A4 (en) | 2017-12-31 | 2021-01-13 | Hangzhou DAC Biotech Co, Ltd | CONJUGATE OF ANALOGUE OF TUBULYSIN WITH BRANCHED LINKS |
| WO2019243431A1 (en) | 2018-06-20 | 2019-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for treating melanoma |
| EA202190189A1 (ru) | 2018-07-05 | 2021-04-16 | Ханчжоу Дэк Биотек Ко., Лтд | Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты |
| WO2020046770A1 (en) | 2018-08-31 | 2020-03-05 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Kinase activity in tumors |
| IL282182B2 (en) | 2018-10-12 | 2025-09-01 | Hangzhou Dac Biotech Co Ltd | Cytotoxic drug conjugates with a bis linkage |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| CA3128264A1 (en) | 2019-01-31 | 2020-08-06 | Hangzhou Dac Biotech Co., Ltd | A conjugate of an amanita toxin with branched linkers |
| PH12021500050A1 (en) | 2019-06-24 | 2022-05-02 | Hangzhou Dac Biotech Co Ltd | A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers |
| CN114040781A (zh) | 2019-06-24 | 2022-02-11 | 杭州多禧生物科技有限公司 | Tubulysin衍生物与细胞结合分子偶联物的制剂配方 |
| WO2021011634A1 (en) | 2019-07-15 | 2021-01-21 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| KR20210053252A (ko) | 2019-11-01 | 2021-05-11 | (주)셀레메디 | 면역 관문 분자와 결합 가능한 분자가 융합된 단백질 및 이의 용도 |
| WO2021086159A1 (ko) | 2019-11-01 | 2021-05-06 | (주)셀레메디 | 면역 관문 분자와 결합 가능한 분자가 융합된 단백질 및 이의 용도 |
| CN115443150A (zh) * | 2019-12-17 | 2022-12-06 | 德克萨斯大学系统董事会 | 新型ddr1抗体和其用途 |
| AU2021225870A1 (en) | 2020-02-27 | 2022-10-20 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
| US20210284731A1 (en) | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| BR112022025583A2 (pt) | 2020-06-19 | 2023-01-03 | Hangzhou Dac Biotech Co Ltd | Conjugado de molécula de ligação à superfície celular e análogo de camptotecina, composto conjugável, célula de tumor, composição farmacêutica, agente quimioterapêutico, e, agentes sinergísticos |
| CN116723839A (zh) | 2020-10-14 | 2023-09-08 | C4医药公司 | 用于降解靶蛋白质的三环杂双官能化合物 |
| WO2022092974A1 (ko) | 2020-10-30 | 2022-05-05 | (주)셀레메디 | 항체 유사 단백질 및 그 용도 |
| WO2022135332A1 (zh) | 2020-12-21 | 2022-06-30 | 映恩生物制药（苏州）有限公司 | 一种甾体偶联物 |
| CN114807042B (zh) | 2021-01-22 | 2024-09-03 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体改造的nk细胞及其制备方法与应用 |
| WO2022171101A1 (zh) | 2021-02-10 | 2022-08-18 | 映恩生物制药（苏州）有限公司 | 一种甾体偶联物 |
| NL2028075B1 (en) | 2021-04-26 | 2022-11-03 | Alphathera Ag | Targeting system for cancer comprising a radioisotope |
| WO2022235059A1 (ko) | 2021-05-03 | 2022-11-10 | (주)셀레메디 | 폐암의 예방 또는 치료용 약학 조성물 |
| JP2024524301A (ja) | 2021-07-02 | 2024-07-05 | ラエクナ セラピューティクス シャンハイ カンパニー リミテッド | 活性化肝星細胞（ｈｓｃ）の枯渇及びその使用 |
| CN120463762A (zh) | 2021-08-26 | 2025-08-12 | 映恩生物科技(上海)有限公司 | 一种甾体化合物及其缀合物 |
| US20250179114A1 (en) | 2021-09-14 | 2025-06-05 | Duality Biologics (Suzhou) Co., Ltd. | Anti-Inflammatory Compound and Use Thereof |
| EP4405487A4 (en) | 2021-09-26 | 2025-12-03 | Wuxi Biologics Ireland Ltd | IL-2 VARIANTS AND THEIR FUSING PROTEINS |
| WO2023061478A1 (zh) | 2021-10-15 | 2023-04-20 | 先声再明医药有限公司 | 三环类化合物 |
| EP4426727A2 (en) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| WO2023163873A1 (en) | 2022-02-23 | 2023-08-31 | Mayo Foundation For Medical Education And Research | Synergistic drug combinations to treat cancer |
| JP2025507733A (ja) | 2022-02-28 | 2025-03-21 | ウーシー バイオロジクス アイルランド リミテッド | Ｉｌ－１５変異体を含むヘテロ二量体ポリペプチド錯体とその使用 |
-
2020
- 2020-12-17 CN CN202080094867.1A patent/CN115443150A/zh active Pending
- 2020-12-17 JP JP2022537312A patent/JP2023508277A/ja active Pending
- 2020-12-17 WO PCT/US2020/065618 patent/WO2021127185A1/en not_active Ceased
- 2020-12-17 BR BR112022011037A patent/BR112022011037A2/pt unknown
- 2020-12-17 CA CA3160181A patent/CA3160181A1/en active Pending
- 2020-12-17 IL IL294019A patent/IL294019A/en unknown
- 2020-12-17 US US17/757,510 patent/US20230130372A1/en active Pending
- 2020-12-17 MX MX2022007353A patent/MX2022007353A/es unknown
- 2020-12-17 EP EP20903632.6A patent/EP4076526A4/en active Pending
- 2020-12-17 AU AU2020407089A patent/AU2020407089B2/en active Active
-
2023
- 2023-02-28 US US18/176,072 patent/US12331130B2/en active Active
-
2024
- 2024-08-14 JP JP2024135167A patent/JP2024164067A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12331130B2 (en) | 2025-06-17 |
| US20230235078A1 (en) | 2023-07-27 |
| WO2021127185A1 (en) | 2021-06-24 |
| JP2024164067A (ja) | 2024-11-26 |
| JP2023508277A (ja) | 2023-03-02 |
| US20230130372A1 (en) | 2023-04-27 |
| CA3160181A1 (en) | 2021-06-24 |
| CN115443150A (zh) | 2022-12-06 |
| AU2020407089A1 (en) | 2022-06-30 |
| IL294019A (en) | 2022-08-01 |
| MX2022007353A (es) | 2022-09-19 |
| EP4076526A4 (en) | 2024-07-03 |
| EP4076526A1 (en) | 2022-10-26 |
| AU2020407089B2 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022011037A2 (pt) | Anticorpos ddr1 novos e usos dos mesmos | |
| BR112021023229A2 (pt) | Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso | |
| BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
| BR112019000071A2 (pt) | conjugados adjuvantes de anticorpo | |
| BR112019005670A2 (pt) | anticorpos anti-muc16 (mucina 16) | |
| EA201990781A1 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| BR112016016207A2 (pt) | Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos | |
| BR112017019617A2 (pt) | Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada | |
| BR112015007672A2 (pt) | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso | |
| JOP20220161A1 (ar) | جسم مضاد لـ lilrb1 واستخداماته | |
| MX2024007724A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado | |
| BR112019002168A2 (pt) | anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina | |
| BR112014018481A2 (pt) | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso | |
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| CY1118053T1 (el) | Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea | |
| MX2021005323A (es) | Metodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn. | |
| MX2021010893A (es) | Anticuerpo biespecifico enlazado especificamente a vegf y ang2. | |
| BR112018070948A2 (pt) | anticorpos anti-psma e utilização dos mesmos | |
| BR112013021350A2 (pt) | anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes | |
| BR112023004415A2 (pt) | Moléculas terapêuticas de ligação a b7-h4 | |
| MY202157A (en) | Anti-pd-l1 antibody and use thereof | |
| JOP20210159A1 (ar) | أجسام مضادة لـ pmel17 ومترافقات منها | |
| BR112022013298A2 (pt) | Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos | |
| BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
| BR112022013403A2 (pt) | Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos |